| Issue Date | Title | Author(s) |
| 19-Mar-2015 | Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma | Smirne, C; Grossi, G; Pinato, DJ; Burlone, ME; Mauri, FA, et al |
| 1-Jul-2019 | Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma | Howell, J; Atkinson, SR; Pinato, DJ; Knapp, S; Ward, C, et al |
| 14-Feb-2017 | Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib. | Howell, J; Pinato, DJ; Ramaswami, R; Arizumi, T; Ferrari, C, et al |
| 2-Mar-2017 | On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study | Howell, J; Pinato, DJ; Ramaswami, R; Bettinger, D; Arizumi, T, et al |
| 1-Jul-2019 | Stereotactic body radiation therapy as an alternative treatment for patients with hepatocellular carcinoma compared to sorafenib: a propensity score analysis | Bettinger, D; Pinato, DJ; Schultheiss, M; Sharma, R; Rimassa, L, et al |
| Feb-2017 | The ALBI grade provides objective hepatic reserve phenotyping across each BCLC stage of hepatocellular carcinoma | Pinato, DJ; Sharma, R; Yen, C; Arizumi, T; Kubota, K, et al |
| 24-Jan-2017 | The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development | Pinato, DJ; Yen, C; Bettinger, D; Ramaswami, R; Arizumi, T, et al |
| 1-Jan-2017 | Treatment-stage migration maximizes survival outcomes in patients with hepatocellular carcinoma treated with sorafenib: an observational study | Yen, C; Sharma, R; Rimassa, L; Arizumi, T; Bettinger, D, et al |